ArticleBlood cancer journal2015

Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins.

M Dwojak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.